Search results for "ERYTHROPOIETIN"

showing 10 items of 113 documents

Role of Erythropoietin in Cerebral Glioma: An Innovative Target in Neuro-Oncology

2019

Background: Erythropoietin (EPO) is a cytokine primarily involved in the regulation of erythropoiesis. In response to hypoxia–ischemia, hypoxia-inducible factor 1 induces EPO production, which, in turn, inhibits apoptosis of erythroid progenitor cells. By the same mechanism and acting through other signaling pathways, EPO exerts neuroprotective effects. Increased resistance to hypoxia and decreased apoptosis are thought to be important mechanisms for tumor progression, including malignant glioma. Because recent studies have demonstrated that EPO and its receptor (EPOR) are expressed in several tumors and can promote tumor growth, in the present study, we investigated EPO and EPOR expression…

AdultMalemedicine.medical_treatmentBlotting WesternErythropoietin receptor03 medical and health sciences0302 clinical medicineGliomaCell Line TumormedicineReceptors ErythropoietinAnimalsHumansErythropoietinAgedPlatelet Endothelial Cell Adhesion Moleculebusiness.industryBrain NeoplasmsGliomaMiddle Agedmedicine.diseaseImmunohistochemistryRats Inbred F344Recombinant ProteinsErythropoietin receptorTumor BurdenPlatelet Endothelial Cell Adhesion Molecule-1Disease Models AnimalCytokineKi-67 AntigenApoptosisErythropoietinTumor progressionErythropoietin; Erythropoietin receptor; Glioma030220 oncology & carcinogenesisCancer researchErythropoiesisSurgeryFemaleNeurology (clinical)business030217 neurology & neurosurgeryNeoplasm Transplantationmedicine.drugErythropoietin Erythropoietin receptor Glioma
researchProduct

Effects of anemia correction with epoetin beta in patients receiving radiochemotherapy for advanced cervical cancer

2007

Patients with cervical cancer frequently suffer from anemia. This two-stage, adaptive-design study investigated the effect of anemia correction with epoetin beta on treatment outcomes. Patients with stage IIB–IVA cervical cancer received radiochemotherapy (RCT) and were randomized to epoetin 150 IU/kg three times weekly (n = 34) or standard care (control; n = 40) for up to 12 weeks. Primary end point for stage 1 aimed to establish a correlation between anemia correction and treatment failure (no complete response or relapsing within 6 months after RCT initiation) as a proof of concept before moving into stage 2. Secondary end points included progression/relapse-free survival, overall surviv…

Adultmedicine.medical_specialtyAnemiaInjections Subcutaneousmedicine.medical_treatmentUterine Cervical NeoplasmsRisk AssessmentGastroenterologyDrug Administration Schedulelaw.inventionRandomized controlled trialReference ValueslawInternal medicinemedicineClinical endpointHumansAdverse effectErythropoietinSurvival analysisNeoplasm StagingProbabilityCervical cancerChemotherapyEpoetin betaDose-Response Relationship Drugbusiness.industryObstetrics and GynecologyAnemiaMiddle Agedmedicine.diseaseCombined Modality TherapyImmunohistochemistrySurvival AnalysisRecombinant ProteinsSurgeryLogistic ModelsTreatment OutcomeOncologyChemotherapy AdjuvantFemaleRadiotherapy AdjuvantbusinessFollow-Up StudiesInternational Journal of Gynecologic Cancer
researchProduct

Intravenous recombinant erythropoietin does not lead to an increase in cerebrospinal fluid erythropoietin concentration

2000

No abstract

Adultmedicine.medical_specialtyUltrasonography Doppler Transcranialmedicine.medical_treatmentSkull NeoplasmsElectrolytesIntraoperative PeriodCerebrospinal fluidPharmacokineticsInternal medicinemedicineHumansPulseRecombinant erythropoietinErythropoietinTransplantationChemotherapybusiness.industrySettore MED/27 - NeurochirurgiaErythropoietin transcranial dopplerRecombinant ProteinsEndocrinologyCytokineBlood-Brain BarrierNephrologyErythropoietinCerebrovascular CirculationInjections IntravenousIntravenous recombinant erythropoietin; cerebrospinal fluid; erythropoietin concentration.Femalebusinessmedicine.drug
researchProduct

Anemia of Chronic Disease: Pathophysiology and Laboratory Diagnosis

2005

Classic iron deficiency (ID) does not represent a challenge for the laboratory and physicians. The anemia that accompanies infection, inflammation, and cancer, commonly termed anemia of chronic disease (ACD), features apparently normal or increased iron stores. However, 20% of these patients have iron-restricted erythropoiesis (functional ID), an imbalance between the iron requirements of the erythroid marrow and the actual iron supply. Functional ID leads to a reduction in red cell hemoglobiniza-tion, causing hypochromic microcytic anemia. The diagnosis of functional ID in real time is based on measuring the hemoglobin content of reticulocytes. An examination of the biochemical markers of …

AnemiaIronClinical BiochemistrymedicineHomeostasisHumansErythropoiesisErythropoietinSoluble transferrin receptorbiologybusiness.industryBiochemistry (medical)AnemiaHematologyIron deficiencymedicine.diseaseHypochromic microcytic anemiaFerritinErythropoietinChronic DiseaseImmunologybiology.proteinErythropoiesisbusinessAnemia of chronic diseasemedicine.drugLaboratory Hematology
researchProduct

The erythropoietin and regenerative medicine: a lesson from fish

2009

Background Erythropoietin (EPO), the main haematopoietic growth factor for the proliferation and differentiation of erythroid progenitor cells, is also known for its angiogenic and regenerative properties. Materials and methods In this study, we aimed to test the regenerative effects of EPO administration in an experimental model of Sea bass (Dicentrarchus labrax) subjected to amputation of the caudal fin. Results Erythropoietin-treated fishes (3000 UI of human recombinant EPO-alpha immediately after cutting and after 15 days) showed an increased growth rate of their fins compared with those untreated (ANOVA variance: P :0 AE01 vs. P :0 AE04). By analysing fin length at established times (1…

Angiogenesismedicine.medical_treatmentClinical BiochemistryNeovascularization PhysiologicRegenerative MedicineModels BiologicalBiochemistryAndrologyangiogenesisfin growthFibrosismedicineAnimalsSea bassbiologySettore MED/27 - NeurochirurgiaMedicine (all)Growth factorFishesGeneral MedicineSea bamedicine.diseasebiology.organism_classificationImmunohistochemistryEPO regenerative medicineangiogenesis; Erythropoietin; tissue regeneration; fishAngiogenesiHaematopoiesisErythropoietinregenerationImmunologyBassDicentrarchuserythropoietinStem cellsea bassmedicine.drugEuropean Journal of Clinical Investigation
researchProduct

The role of erythropoietin in aneurysmal subarachnoid haemorrhage: from bench to bedside.

2014

Subarachnoid haemorrhage (SAH) caused by a ruptured aneurysm accounts for only 5% of strokes, but occurs at a fairly young age and carries a poor prognosis. Delayed cerebral ischaemia (DCI) is an important cause of death and dependence after aneurysmal SAH. The current mainstay of preventing DCI is nimodipine and maintenance of normovolemia, but even with this strategy DCI occurs in a considerable proportion of patients. Several drugs have been developed that have the potential to limit cerebral vasospasm and delayed ischaemic neurologic defi cit, thus improving outcome for patients. However, although numerous agents can prevent arterial narrowing and/or block the excitatory cascade of even…

AnimalSettore MED/27 - NeurochirurgiaMedicine (all)Subarachnoid HemorrhageBrain IschemiaStrokeAnimalsHumansVasospasm IntracranialSurgeryNeurology (clinical)ErythropoietinCerebral aneurysmHumanActa neurochirurgica. Supplement
researchProduct

Regression Modeling of the Antioxidant-to-Nephroprotective Relation Shows the Pivotal Role of Oxidative Stress in Cisplatin Nephrotoxicity

2021

The clinical utility of the chemotherapeutic drug cisplatin is significantly limited by its nephrotoxicity, which is characterized by electrolytic disorders, glomerular filtration rate decline, and azotemia. These alterations are consequences of a primary tubulopathy causing injury to proximal and distal epithelial cells, and thus tubular dysfunction. Oxidative stress plays a role in cisplatin nephrotoxicity and cytotoxicity, but its relative contribution to overall toxicity remains unknown. We studied the relation between the degree of oxidative reduction (provided by antioxidant treatment) and the extent of nephrotoxicity amelioration (i.e., nephroprotection) by means of a regression anal…

AntioxidantPhysiologymedicine.medical_treatmentClinical BiochemistrycisplatinOxidative phosphorylationRM1-950Pharmacologymedicine.disease_causeBiochemistryArticleNephrotoxicitypreventionpreclinicalMedicineMolecular BiologyCisplatinlinear fitbusiness.industrynephrotoxicityCell Biologymedicine.diseaseantioxidantsErythropoietinToxicityAzotemiaTherapeutics. PharmacologybusinessOxidative stressmedicine.drugAntioxidants
researchProduct

Amelioration of spinal cord compressive injury by pharmacological preconditioning with erythropoietin and a nonerythropoietic erythropoietin derivati…

2006

Object Spinal cord injury (SCI) is a devastating clinical syndrome for which no truly efficacious therapy has yet been identified. In preclinical studies, erythropoietin (EPO) and its nonerythropoietic derivatives asialoEPO and carbamylated EPO have markedly improved functional outcome when administered after compressive SCI. However, an optimum treatment paradigm is currently unknown. Because the uninjured spinal cord expresses a high density of EPO receptor (EPOR) in the basal state, signaling through these existing receptors in advance of injury (pharmacological preconditioning) might confer neuroprotection and therefore be potentially useful in situations of anticipated damage. Methods…

Blotting WesternAsialoglycoproteinsPharmacologyNeuroprotectionCentral nervous system diseaseImmunoenzyme TechniquesRats Sprague-DawleySpinal cord compressionReceptors ErythropoietinMedicineAnimalsReceptorSpinal cord injuryErythropoietinSpinal Cord InjuriesAnalysis of Variancebusiness.industryGeneral MedicineSpinal cordmedicine.diseaseErythropoietin receptorRatsDisease Models Animalmedicine.anatomical_structureNeuroprotective AgentsErythropoietinImmunologybusinessmedicine.drugJournal of neurosurgery. Spine
researchProduct

Neuroprotective effect of erythropoietin and darbepoetin alfa after experimental intracerebral hemorrhage.

2009

OBJECTIVE: Intracerebral hemorrhage (ICH) is a devastating clinical syndrome for which no truly efficacious therapy has yet been identified. In preclinical studies, erythropoietin (EPO) and its long-lasting analog, darbepoetin alfa, have been demonstrated to be neuroprotective in several models of neuronal insult. The objectives of this study were to analyze whether the systemic administration of recombinant human EPO (rHuEPO) and its long-lasting derivative darbepoetin alfa expedited functional recovery and brain damage in a rat model of ICH. METHODS: Experimental ICH was induced in rats by injecting autologous blood into the right striatum under stereotactic guidance. Subsequently, animal…

Brain InfarctionMaleDarbepoetin alfaBrain EdemaBrain damageNeuroprotectionDrug Administration ScheduleCentral nervous system diseaseRats Sprague-DawleyBlood Transfusion AutologousErythropoietin; Erythropoietin derivative; Intracerebral hemorrhage; Neuroprotectionhemic and lymphatic diseasesEdemamedicineAnimalsHumansDarbepoetin alfaErythropoietinCerebral HemorrhageIntracerebral hemorrhagebusiness.industryBasal Ganglia HemorrhageBrainmedicine.diseaseNeuroprotectionCorpus StriatumRecombinant ProteinsRatsErythropoietin derivativeDisease Models AnimalNeuroprotective AgentsTreatment OutcomeErythropoietinAnesthesiaErythropoietin Erythropoietin derivative Intracerebral hemorrhage NeuroprotectionSystemic administrationHematinicsSurgeryNeurology (clinical)medicine.symptomIntracerebral hemorrhagebusinessmedicine.drugNeurosurgery
researchProduct

Prevention of chemotherapy-induced anemia and thrombocytopenia by constant administration of stem cell factor.

2011

Abstract Purpose: Chemotherapy-induced apoptosis of immature hematopoietic cells is a major cause of anemia and thrombocytopenia in cancer patients. Although hematopoietic growth factors such as erythropoietin and colony-stimulating factors cannot prevent the occurrence of drug-induced myelosuppression, stem cell factor (SCF) has been previously shown to protect immature erythroid and megakaryocytic cells in vitro from drug-induced apoptosis. However, the effect of SCF in vivo as a single myeloprotective agent has never been elucidated. Experimental Design: The ability of SCF to prevent the occurrence of chemotherapy-induced anemia and thrombocytopenia was tested in a mouse model of cisplat…

Cancer ResearchAnemiamedicine.medical_treatmentSCF Bcl-2/Bcl-XL–positiveStem cell factorAntineoplastic AgentsBone Marrow CellsInbred C57BLDrug Administration ScheduleMiceSettore MED/04 - PATOLOGIA GENERALEmedicineAnimalsCisplatinErythroid Precursor CellsChemotherapyStem Cell Factorbusiness.industryAnemiamedicine.diseaseAnemia; Animals; Antineoplastic Agents; Bone Marrow Cells; Cisplatin; Drug Administration Schedule; Erythroid Precursor Cells; Female; Megakaryocytes; Mice; Mice Inbred C57BL; Stem Cell Factor; Thrombocytopenia; Oncology; Cancer ResearchThrombocytopeniaMice Inbred C57BLHaematopoiesisCytokinemedicine.anatomical_structureOncologyErythropoietinImmunologyCancer researchFemaleBone marrowCisplatinbusinessMegakaryocytesmedicine.drugClinical cancer research : an official journal of the American Association for Cancer Research
researchProduct